Figures & data
Figure 1. Study design. Abbreviations. AD, Anti-depressant; MDD, Major depressive disorder; LOT, Line of therapy; TRD, Treatment-resistant depression.
Figure 2. Sample selection. Abbreviations. AD/AP, Anti-depressant/MDD-indicated anti-psychotic; MDD, Major depressive disorder; TRD, Treatment-resistant depression. (a) Exclusionary diagnoses were psychosis, schizophrenia, bipolar disorder, dementia and Tourette syndrome. (b) All included episodes must have begun and ended during the study period and, in addition to a first eligible MDD diagnosis, must have had a subsequent MDD diagnosis or AD/AP medication claim.
Table 1. Patient characteristics of MDD patients with at least one MDD episode.
Figure 3. Average duration and healthcare costs of newly observed treatment: MDD episodes. Abbreviations. ER, Emergency room; MDD, Major depressive disorder; SD, Standard deviation; TRD, Treatment-resistant depression.
Data availability statement
Data for this study were available to the authors via third-party license from IBM MarketScan Research Databases, a commercial data provider in the US, and Janssen Pharmaceuticals, who has a license for analysis of the de-identified IBM MarketScan Commercial and Medicare Supplemental databases. As such, the authors cannot provide the raw data; however, other researchers may access the data by purchase through IBM, and the inclusion criteria specified in the methods would allow them to identify the same cohort of patients. Interested individuals may visit https://www.ibm.com/watson/health/ for more information on accessing IBM MarketScan Research Databases.